Wyllie Cornwell - Pfizer Independent Director

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Report: 28th of July 2020  

  Director
Mr. Wyllie Don Cornwell is an Independent Director of Pfizer Inc. He was Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporationrationration from 1988 until his retirement in August 2009, and served as Vice Chairman of the Board until December 2009. Director of American International Group, Inc. and Avon Products, Inc. Director of the Edna McConnell Clark Foundation. Director of the Wallace Foundation from 2002 until 2012 and previously served as a Director of CVS Caremark for over 10 years. Trustee of Big Brothers Big Sisters of New York City. Through Mr. Cornwells 38year career as an entrepreneur driving the growth of a consumerfocused media company, an executive in the investment banking industry and a director of several significant consumer product and healthcare companies, he has valuable business, leadership and management experience and brings important perspectives on the issues facing Pfizer. Mr. Cornwell founded and built Granite, a consumerfocused media company, through acquisitions and operating growth, enabling him to provide insight and guidance on strategic direction and growth
Age: 71  Director Since 1997      
212 733-2323  www.pfizer.com
Cornwell?s strong financial background, including his work at Goldman Sachs prior to cofounding Granite and his service and leadership on the audit, finance and investment committees of other companies, also provides financial expertise to the Board, including an understanding of financial statements, corporate finance, accounting and capital markets.

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 5.78 % which means that on every $100 spent on asset it made $5.78 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 25.41 %, implying that it generated $25.41 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 8.28. Pfizer Current Assets are expected to decrease significantly based on the last few years of reporting. The past year's Current Assets were at 32.8 Billion. The current year Tax Assets is expected to grow to about 6.1 B, whereas Goodwill and Intangible Assets are expected to decline to about 89.2 B. Pfizer Tax Liabilities is expected to decrease significantly based on the last few years of reporting. The past year's Tax Liabilities was at 18.68 Billion
The company has 52.29 B in debt with debt to equity (D/E) ratio of 0.8, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.0, demonstrating that it may have difficulties to pay its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Allan ObermanDr Reddys Laboratories
2019
Anthony ColesRegeneron Pharmaceuticals
2017
David AltshulerVertex Pharmaceuticals Incorpor
2015
Charles BakerRegeneron Pharmaceuticals
N/A
Michael JandernoaPerrigo Company Plc
2007
Bruce CarterDr Reddys Laboratories
2008
Carol DavidsonAllergan Plc
2018
Catherine KlemaAllergan Plc
2016
Joseph GoldsteinRegeneron Pharmaceuticals
1991
William YoungVertex Pharmaceuticals Incorpor
2014
Sridar IyengarDr Reddys Laboratories
2011
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Huda ZoghbiRegeneron Pharmaceuticals
2016
Fred WeissAllergan Plc
2013
Ashok GangulyDr Reddys Laboratories
2009
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
George SingRegeneron Pharmaceuticals
1988
Shlomo YanaiPerrigo Company Plc
N/A
Robert ScullyZoetis Inc
2013
Elaine UllianVertex Pharmaceuticals Incorpor
2011
J MoreauDr Reddys Laboratories
2007

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
3 days ago
Traded for 8.62
GM   
Sold over 100 shares of
3 days ago
Traded for 25.24
XOM   
Sold over 60 shares of
3 days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
3 days ago
Traded for 28.82
MSFT   
Sold few shares of
3 days ago
Traded for 206.26
Please check Your Equity Center. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page